DLA
Douglas Lane & Associates’s GSK GSK Stock Holding History
Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $50.6M | Sell |
1,317,109
-204,417
| -13% | -$7.85M | 0.73% | 55 |
|
2025
Q1 | $58.9M | Sell |
1,521,526
-106,978
| -7% | -$4.14M | 0.87% | 46 |
|
2024
Q4 | $55.1M | Sell |
1,628,504
-544,979
| -25% | -$18.4M | 0.78% | 48 |
|
2024
Q3 | $88.9M | Sell |
2,173,483
-34,927
| -2% | -$1.43M | 1.22% | 27 |
|
2024
Q2 | $85M | Sell |
2,208,410
-12,141
| -0.5% | -$467K | 1.21% | 24 |
|
2024
Q1 | $95.2M | Sell |
2,220,551
-15,613
| -0.7% | -$669K | 1.35% | 21 |
|
2023
Q4 | $82.9M | Sell |
2,236,164
-75,727
| -3% | -$2.81M | 1.28% | 26 |
|
2023
Q3 | $83.8M | Buy |
2,311,891
+87,789
| +4% | +$3.18M | 1.41% | 21 |
|
2023
Q2 | $79.3M | Buy |
2,224,102
+61,812
| +3% | +$2.2M | 1.28% | 28 |
|
2023
Q1 | $76.9M | Buy |
2,162,290
+108,193
| +5% | +$3.85M | 1.28% | 29 |
|
2022
Q4 | $72.2M | Buy |
2,054,097
+464,538
| +29% | +$16.3M | 1.21% | 35 |
|
2022
Q3 | $46.8M | Sell |
1,589,559
-248,476
| -14% | -$7.31M | 0.86% | 46 |
|
2022
Q2 | $80M | Buy |
1,838,035
+43,756
| +2% | +$1.9M | 1.36% | 24 |
|
2022
Q1 | $78.2M | Buy |
1,794,279
+52,032
| +3% | +$2.27M | 1.1% | 33 |
|
2021
Q4 | $76.8M | Buy |
1,742,247
+93,958
| +6% | +$4.14M | 1.02% | 33 |
|
2021
Q3 | $63M | Buy |
1,648,289
+166,794
| +11% | +$6.37M | 0.9% | 42 |
|
2021
Q2 | $59M | Buy |
1,481,495
+137,474
| +10% | +$5.47M | 0.83% | 47 |
|
2021
Q1 | $48M | Buy |
1,344,021
+177,361
| +15% | +$6.33M | 0.74% | 56 |
|
2020
Q4 | $42.9M | Buy |
1,166,660
+78,437
| +7% | +$2.89M | 0.72% | 53 |
|
2020
Q3 | $41M | Buy |
1,088,223
+142,252
| +15% | +$5.35M | 0.81% | 47 |
|
2020
Q2 | $38.6M | Buy |
945,971
+81,965
| +9% | +$3.34M | 0.83% | 46 |
|
2020
Q1 | $32.7M | Buy |
864,006
+118,400
| +16% | +$4.49M | 0.86% | 45 |
|
2019
Q4 | $35M | Buy |
745,606
+338,569
| +83% | +$15.9M | 0.65% | 61 |
|
2019
Q3 | $17.4M | Buy |
+407,037
| New | +$17.4M | 0.35% | 85 |
|